Study guide

13.3 Glaucoma, Anti-Infective, and Anti-Inflammatory Agents

COA Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: COA Orientation and Exam Strategy

1.1 Current COA Exam Facts 1.2 Eligibility, Application, and Scheduling 1.3 Blueprint Domains and Weighting 1.4 Question Style and Score Report Thinking 1.5 Study Calendar and Practice Plan

2 Chapter 2: History and Documentation

2.1 History and Documentation Overview 2.2 Core Workflows and Decision Points 2.3 Scenario Practice for History and Documentation 2.4 Common Traps in History and Documentation 2.5 Practice Drills and Readiness Markers

3 Chapter 3: Visual Assessment

3.1 Visual Assessment Overview 3.2 Core Workflows and Decision Points 3.3 Scenario Practice for Visual Assessment 3.4 Common Traps in Visual Assessment 3.5 Practice Drills and Readiness Markers

4 Chapter 4: Visual Field Testing

4.1 Visual Field Testing Overview 4.2 Core Workflows and Decision Points 4.3 Scenario Practice for Visual Field Testing 4.4 Common Traps in Visual Field Testing 4.5 Practice Drills and Readiness Markers

5 Chapter 5: Pupil Assessment

5.1 Pupil Assessment Overview 5.2 Core Workflows and Decision Points 5.3 Scenario Practice for Pupil Assessment 5.4 Common Traps in Pupil Assessment 5.5 Practice Drills and Readiness Markers

6 Chapter 6: Tonometry

6.1 Tonometry Overview 6.2 Core Workflows and Decision Points 6.3 Scenario Practice for Tonometry 6.4 Common Traps in Tonometry 6.5 Practice Drills and Readiness Markers

7 Chapter 7: Keratometry

7.1 Keratometry Overview 7.2 Core Workflows and Decision Points 7.3 Scenario Practice for Keratometry 7.4 Common Traps in Keratometry 7.5 Practice Drills and Readiness Markers

8 Chapter 8: Lensometry

8.1 Lensometry Overview 8.2 Core Workflows and Decision Points 8.3 Scenario Practice for Lensometry 8.4 Common Traps in Lensometry 8.5 Practice Drills and Readiness Markers

9 Chapter 9: Biometry

9.1 Biometry Overview 9.2 Core Workflows and Decision Points 9.3 Scenario Practice for Biometry 9.4 Common Traps in Biometry 9.5 Practice Drills and Readiness Markers

10 Chapter 10: Diagnostic Ultrasound

10.1 Diagnostic Ultrasound Overview 10.2 Core Workflows and Decision Points 10.3 Scenario Practice for Diagnostic Ultrasound 10.4 Common Traps in Diagnostic Ultrasound 10.5 Practice Drills and Readiness Markers

11 Chapter 11: Supplemental Testing

11.1 Supplemental Testing Overview 11.2 Core Workflows and Decision Points 11.3 Scenario Practice for Supplemental Testing 11.4 Common Traps in Supplemental Testing 11.5 Practice Drills and Readiness Markers

12 Chapter 12: Microbiology

12.1 Microbiology Overview 12.2 Core Workflows and Decision Points 12.3 Scenario Practice for Microbiology 12.4 Common Traps in Microbiology 12.5 Practice Drills and Readiness Markers

13 Chapter 13: Pharmacology

13.1 Pharmacology Overview 13.2 Mydriatics, Cycloplegics, and Anesthetics 13.3 Glaucoma, Anti-Infective, and Anti-Inflammatory Agents 13.4 Stains, Instillation Technique, and Safety Traps 13.5 Practice Drills and Readiness Markers

14 Chapter 14: Surgical Assisting

14.1 Surgical Assisting Overview 14.2 Core Workflows and Decision Points 14.3 Scenario Practice for Surgical Assisting 14.4 Common Traps in Surgical Assisting 14.5 Practice Drills and Readiness Markers

15 Chapter 15: Ophthalmic Patient Services and Education

15.1 Ophthalmic Patient Services and Education Overview 15.2 Core Workflows and Decision Points 15.3 Scenario Practice for Ophthalmic Patient Services and Education 15.4 Common Traps in Ophthalmic Patient Services and Education 15.5 Practice Drills and Readiness Markers

16 Chapter 16: Optics and Spectacles

16.1 Optics and Spectacles Overview 16.2 Core Workflows and Decision Points 16.3 Scenario Practice for Optics and Spectacles 16.4 Common Traps in Optics and Spectacles 16.5 Practice Drills and Readiness Markers

17 Chapter 17: Contact Lenses

17.1 Contact Lens Types, Parameters, and Oxygen 17.2 Fitting Workflows: K Readings, Tear Lens, and the SAM/FAP Rule 17.3 Insertion, Removal, Care Systems, and Wear Schedules 17.4 Complications: Hypoxia, Infiltrates, and Corneal Ulcers 17.5 Specialty Lenses, Multifocals, and Readiness Drills

18 Chapter 18: Equipment Maintenance and Repair

18.1 Equipment Maintenance and Repair Overview 18.2 Core Workflows and Decision Points 18.3 Scenario Practice for Equipment Maintenance and Repair 18.4 Common Traps in Equipment Maintenance and Repair 18.5 Practice Drills and Readiness Markers

19 Chapter 19: Medical Ethics, Legal, and Regulatory Issues

19.1 Medical Ethics, Legal, and Regulatory Issues Overview 19.2 Core Workflows and Decision Points 19.3 Scenario Practice for Medical Ethics, Legal, and Regulatory Issues 19.4 Common Traps in Medical Ethics, Legal, and Regulatory Issues 19.5 Practice Drills and Readiness Markers

20 Chapter 20: General Medical Knowledge

20.1 General Medical Knowledge Overview 20.2 Medical Terminology, Anatomy, and Physiology 20.3 Systemic Disease with Ocular Manifestations 20.4 Pharmacology and Medical Emergencies 20.5 Microbiology, Infection Control, and Readiness Drills

21 Chapter 21: Refraction

21.1 Refraction Overview 21.2 Core Workflows and Decision Points 21.3 Scenario Practice for Refraction 21.4 Common Traps in Refraction 21.5 Practice Drills and Readiness Markers

22 Chapter 22: Ophthalmic Imaging

22.1 Ophthalmic Imaging Overview 22.2 Core Workflows and Decision Points 22.3 Scenario Practice for Ophthalmic Imaging 22.4 Common Traps in Ophthalmic Imaging 22.5 Practice Drills and Readiness Markers

23 Chapter 23: Ocular Motility Testing

23.1 Ocular Motility Testing Overview 23.2 Core Workflows and Decision Points 23.3 Scenario Practice for Ocular Motility Testing 23.4 Common Traps in Ocular Motility Testing 23.5 Practice Drills and Readiness Markers

24 Chapter 24: Final Review and Test Day

24.1 Timed Practice Strategy 24.2 Last-Week Review Map 24.3 Exam-Day Checklist 24.4 After the Exam and Next Steps

13.3 Glaucoma, Anti-Infective, and Anti-Inflammatory Agents

Key Takeaways Explain This Topic AI

Glaucoma drops lower intraocular pressure by reducing aqueous production (beta-blockers, alpha agonists, carbonic anhydrase inhibitors) or increasing outflow (prostaglandins, miotics).

Timolol is contraindicated in asthma, COPD, and bradycardia/heart block because of systemic beta-blockade.

Prostaglandin analogs like latanoprost are first-line and can darken the iris and lengthen eyelashes.

Fluoroquinolones, aminoglycosides, and macrolides treat bacterial infection; corticosteroids reduce inflammation but raise IOP and worsen herpes simplex keratitis.

Last updated: June 2026

  • 13.3 Glaucoma, Anti-Infective, and Anti-Inflammatory Agents
  • Glaucoma medications

Glaucoma treatment lowers intraocular pressure (IOP) by one of two strategies: decreasing aqueous humor production or increasing aqueous outflow . Know which class does which.

Class Example Mechanism Key side effect

Prostaglandin analog Latanoprost, bimatoprost Increases uveoscleral outflow Iris darkening, lash growth, redness

  • Beta-blocker Timolol 0.5% Decreases aqueous production Bradycardia, bronchospasm
  • Alpha-2 agonist Brimonidine Decreases production + increases outflow Drowsiness, dry mouth, allergy

Carbonic anhydrase inhibitor Dorzolamide (drop), acetazolamide (oral) Decreases production Stinging; oral form causes tingling, kidney stones

Cholinergic (miotic) Pilocarpine Increases outflow, constricts pupil Brow ache, dim vision, miosis

Timolol is the most-tested contraindication: as a non-selective beta-blocker it can cause systemic bronchospasm and bradycardia , so it is avoided in asthma, COPD, and heart block . Always teach patients punctal occlusion to limit systemic absorption.

Anti-infectives

Antibiotics: Fluoroquinolones (moxifloxacin, ofloxacin) are broad-spectrum and common for bacterial conjunctivitis and corneal ulcers; aminoglycosides (tobramycin, gentamicin) cover gram-negatives; macrolides (erythromycin ointment) are gentle and used in neonates.

Antivirals: Trifluridine and ganciclovir gel treat herpes simplex keratitis (the classic dendritic ulcer).

Antifungals: Natamycin is the standard for fungal keratitis, often after vegetable/plant trauma.

Anti-inflammatory agents

Corticosteroids (prednisolone acetate 1%, dexamethasone) powerfully reduce inflammation but carry three exam-critical risks: they can raise IOP (steroid responders), accelerate cataract formation, and dramatically worsen herpes simplex keratitis by promoting viral replication. NSAIDs (ketorolac, diclofenac) reduce inflammation and pain without raising IOP and are common after cataract surgery to prevent cystoid macular edema.

Antihistamines / mast-cell stabilizers

Drops such as olopatadine relieve allergic conjunctivitis itching by blocking histamine and stabilizing mast cells.

Worked scenario

A patient on chronic prednisolone for uveitis returns with a branching corneal lesion that stains with fluorescein in a dendritic pattern. This is herpes simplex keratitis, and continuing the steroid alone could be vision-threatening. The COA flags this immediately for the physician because steroids worsen active herpetic infection; antiviral therapy is needed. Recognizing the steroid/herpes interaction is a high-value exam point.

Production vs. outflow (a structuring framework)

The single most useful glaucoma concept is sorting drugs by what they do to aqueous humor . Aqueous is made by the ciliary body and drains chiefly through the trabecular meshwork into Schlemm's canal, with a smaller uveoscleral pathway. Drugs that reduce production are beta-blockers, alpha-2 agonists, and carbonic anhydrase inhibitors. Drugs that increase outflow are prostaglandin analogs (uveoscleral route) and miotics like pilocarpine (trabecular route). Brimonidine straddles both. If an exam item asks "which lowers IOP by decreasing aqueous production," timolol and dorzolamide are right and latanoprost is wrong.

Acetazolamide and systemic carbonic anhydrase inhibitors

Acetazolamide is an oral CAI used for acute IOP spikes and angle-closure crises. The COA should know its systemic side effects: paresthesias (tingling fingers and toes), metallic taste, malaise, and risk of kidney stones ; it is a sulfonamide, so sulfa allergy matters. It is far more potent than topical dorzolamide but with more body-wide effects.

Steroid-response and ocular surface points

About one-third of patients are steroid responders whose IOP climbs on topical corticosteroids, which is why steroid use is monitored with pressure checks. NSAIDs avoid this but can rarely cause corneal melts in compromised eyes. For dry eye , artificial tears, cyclosporine, and lifitegrast reduce inflammation and improve the tear film. For allergic conjunctivitis , dual-action antihistamine/mast-cell stabilizers like olopatadine are preferred over decongestant drops, which cause rebound redness with chronic use. Matching the agent to the surface problem is a recurring exam theme.

Recognizing the infection picture

The COA should connect a clinical pattern to the likely drug class. Bacterial conjunctivitis or ulcer shows purulent discharge and responds to antibiotics (fluoroquinolone for an ulcer). Viral conjunctivitis (often adenoviral) is watery, highly contagious, and usually treated supportively, not with antibiotics; herpes simplex shows the dendritic ulcer needing antivirals. Fungal keratitis follows vegetable matter or plant trauma and needs natamycin. Allergic disease itches and is bilateral. When a stem describes the presentation, the antibiotic-versus-antiviral-versus-supportive choice is the point.

Treating a viral pink eye with antibiotics or steroids is a classic wrong answer.

Anti-VEGF and the modern injection clinic

Intravitreal anti-VEGF agents (ranibizumab, aflibercept, bevacizumab) treat wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion by blocking the vascular growth factor that drives leaky neovascular vessels. The COA assists by preparing the sterile field, confirming the correct eye and agent, and monitoring the patient afterward for endophthalmitis warning signs (increasing pain, redness, decreased vision). These injections are among the most common procedures in modern ophthalmology, so recognizing the drug class, its indications, and the post-injection red flags is increasingly exam-relevant.

A reconciliation scenario

A glaucoma patient lists "Cosopt and Xalatan" plus an over-the-counter redness reliever they use daily. You recognize Cosopt as dorzolamide-timolol (a beta-blocker contraindicated in their noted asthma) and Xalatan as latanoprost, and you flag both the asthma conflict and the rebound-redness habit for the physician. Accurate name reconciliation plus contraindication awareness is the defensible action.